氨基苯基-1,3,5-三嗪CFTR激活剂在兔中的促分泌活性及药理学研究用于干眼症
研究在成年新西兰白兔中评估CFTRact-K267的促分泌活性与药理学特征。单次局部给药3 nmol使Schirmer泪液试验泪液分泌增加>5 mm并持续9小时,每日两次给药28天未见快速耐受,角膜表面完整性、厚度、眼压及眼组织学未见改变,第28天药物浓集于角膜和结膜,血液及外周器官未检出。
要点
- 单次局部3 nmol CFTRact-K267使兔泪液分泌增加>5 mm达9小时。
- 每日两次给药28天未见快速耐受,角膜表面完整性、厚度、眼压及眼组织学未见改变。
- 第28天药物浓集于角膜和结膜,血液及外周器官未检出。
核心结论
- 这些研究支持将CFTRact-K267开发为干眼症的促分泌治疗。
研究设计与样本
- 在成年新西兰白兔中进行CFTRact-K267的功能与药理学研究。
- 通过眼表电位差在体内测量CFTR氯离子电导,通过短路电流在离体结膜测量。
- 通过Schirmer泪液试验II测量泪液量,通过液相色谱/质谱测量CFTRact-K267的药代动力学和组织分布。
- 通过每日两次局部给药28天研究毒性特征。
主要发现
- 体内电生理测量和离体结膜测量均显示CFTRact-K267激活CFTR。
- 单次局部剂量3 nmol CFTRact-K267使Schirmer泪液试验泪液分泌增加>5 mm持续9小时,泪液中维持预测治疗浓度。
- 28天每日两次给药后未见快速耐受,角膜表面完整性或厚度、眼压或眼组织学未见改变。
- 第28天CFTRact-K267浓集于角膜和结膜,血液或外周器官未检出。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pharmacological activation of ocular surface cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels is a potential pro-secretory approach to treat dry eye disorders. We previously reported the discovery of aminophenyl-1,3,5-triazines, one of which, N-methyl-N-phenyl-6-(2,2,3,3-tetrafluoropropoxy)-1,3,5-triazine-2,4-diamine (herein called CFTRact-K267), fully activated human wildtype CFTR with EC50 ∼ 30 nM and increased tear volume for 8 hours in mice. Here, functional and pharmacological studies of CFTRact-K267 were done in adult New Zealand white rabbits. METHODS: CFTR chloride conductance was measured in vivo by ocular surface potential differences and in ex vivo conjunctiva by short-circuit current. Tear volume was measured by the Schirmer tear test II and CFTRact-K267 pharmacokinetics and tissue distribution by liquid chromatography/mass spectrometry. Toxicity profile was studied for 28 days with twice-daily topical administration. RESULTS: Electrophysiological measurements in vivo and in ex vivo conjunctiva demonstrated CFTR activation by CFTRact-K267. A single topical dose of 3 nmol CFTRact-K267 increased tear production by >5 mm for 9 hours by the Schirmer tear test, with predicted therapeutic concentrations maintained in tear fluid. No tachyphylaxis was seen following 28-day twice-daily administration, and changes were not observed in corneal surface integrity or thickness, intraocular pressure, or ocular histology. At day 28, CFTRact-K267 was concentrated in the cornea and conjunctiva and was not detectable in blood or peripheral organs. CONCLUSIONS: These studies support the development of CFTRact-K267 as a pro-secretory therapy for dry eye disorders.
引用
- Felix CM, Lee S, Levin MH, et al. Pro-Secretory Activity and Pharmacology in Rabbits of an Aminophenyl-1,3,5-Triazine CFTR Activator for Dry Eye Disorders. Invest Ophthalmol Vis Sci. 2017. PMID: 28873176. doi:10.1167/iovs.17-22525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。